Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 25151571)

1.

Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.

Lee MY, Kang HJ, Park SY, Kim HL, Han E, Lee EK.

Clin Ther. 2014 Sep 1;36(9):1183-94. doi: 10.1016/j.clinthera.2014.07.010. Epub 2014 Aug 21.

PMID:
25151571
2.
4.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

5.

Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.

Chiong JR, Kim S, Lin J, Christian R, Dasta JF.

J Med Econ. 2012;15(2):276-84. doi: 10.3111/13696998.2011.643329. Epub 2011 Dec 8.

PMID:
22111754
6.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators.

N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14.

7.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

8.

Update on tolvaptan for the treatment of hyponatremia.

Dasta JF, Chiong JR, Christian R, Friend K, Lingohr-Smith M, Lin J, Cassidy IB.

Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):399-410. doi: 10.1586/erp.12.30. Review.

PMID:
22971027
9.

Vaptans: a promising therapy in the management of advanced cirrhosis.

Ginès P.

J Hepatol. 2007 Jun;46(6):1150-2. Epub 2007 Mar 28.

PMID:
17445935
11.

Hyponatremia, heart failure, and the role of tolvaptan.

O'Connell JB, Alemayehu A.

Postgrad Med. 2012 Mar;124(2):29-39. doi: 10.3810/pgm.2012.03.2534. Review.

PMID:
22437213
12.

Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Erickson KF, Chertow GM, Goldhaber-Fiebert JD.

Ann Intern Med. 2013 Sep 17;159(6):382-9. doi: 10.7326/0003-4819-159-6-201309170-00004.

13.

Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia.

Bulloch MN, Pinner NA.

Expert Rev Clin Pharmacol. 2010 Sep;3(5):601-12. doi: 10.1586/ecp.10.45.

PMID:
22111741
14.

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.

McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.

Health Technol Assess. 2010 May;14(24):1-162. doi: 10.3310/hta14240. Review.

15.

Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.

Vaghasiya RP, DeVita MV, Michelis MF.

Int Urol Nephrol. 2012 Jun;44(3):865-71. doi: 10.1007/s11255-011-9996-8. Epub 2011 May 24.

PMID:
21607553
16.

Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan.

Friedman B, Cirulli J.

J Crit Care. 2013 Apr;28(2):219.e1-12. doi: 10.1016/j.jcrc.2012.06.001. Epub 2012 Aug 9. Review.

PMID:
22884529
17.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

18.

Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans.

Malhotra I, Gopinath S, Janga KC, Greenberg S, Sharma SK, Tarkovsky R.

Case Rep Endocrinol. 2014;2014:807054. doi: 10.1155/2014/807054. Epub 2014 Jan 8.

19.

Clinical review: the use of vaptans in clinical endocrinology.

Peri A.

J Clin Endocrinol Metab. 2013 Apr;98(4):1321-32. doi: 10.1210/jc.2012-4082. Epub 2013 Feb 11. Review.

PMID:
23401044
20.

An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov model decision analysis.

Kim N, Yang B, Lee T, Kwon S.

BMC Complement Altern Med. 2010 Nov 25;10:74. doi: 10.1186/1472-6882-10-74.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk